当前位置： SCI文献检索 > Clinical Lung Cancer期刊下所有文献 > Importance of quality of life in patients with non-small-cell lung cancer.

Importance of quality of life in patients with non-small-cell lung cancer.

Abstract：

:The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have been accepted for its measurement in parallel with other clinical determinations. However, its use in clinical practice is hindered by various obstacles that need to be overcome. In this article we examine the concept of the quality of life in patients with NSCLC, as well as giving an evaluation and interpretation of the results of various clinical trials. We describe the new technological methods used in daily clinical practice to measure the quality of life.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Camps C,del Pozo N,Blasco A,Blasco P,Sirera R

doi

10.3816/CLC.2009.n.010

subject

Has Abstract

pub_date

2009-03-01 00:00:00

pages

83-90

issue

2

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(11)70085-7

journal_volume

10

pub_type

杂志文章,评审

相关文献

Clinical Lung Cancer文献大全
  • Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma.

    abstract：:Recent developments in the chemotherapy of advanced and metastatic non small-cell lung cancer have led to significant, albeit modest, improvements in survival and quality of life. The plethora of new agents with activity in this disease has led to questions as to how these drugs can best be added to existing regimens....

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.1999.n.009

    authors： Edelman MJ,Gandara DR

    更新日期：1999-11-01 00:00:00

  • Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).

    abstract：BACKGROUND:Elderly patients are underrepresented in trials that establish definitive chemoradiotherapy as the standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC). This study analyzed radiotherapy treatment delivery and outcomes at our institution according to elderly (≥ 70 years old) or youn...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.05.001

    authors： Aridgides PD,Janik A,Bogart JA,Duffy S,Rosenbaum P,Gajra A

    更新日期：2013-11-01 00:00:00

  • Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    abstract：BACKGROUND:Afatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Treatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2018.03.009

    authors： Wu YL,Sequist LV,Tan EH,Geater SL,Orlov S,Zhang L,Lee KH,Tsai CM,Kato T,Barrios CH,Schuler M,Hirsh V,Yamamoto N,O'Byrne K,Boyer M,Mok T,Peil B,Märten A,Chih-Hsin Yang J,Paz-Ares L,Park K

    更新日期：2018-07-01 00:00:00

  • Antisense oligonucleotides in the treatment of non-small-cell lung cancer.

    abstract：:Antisense oligonucleotides (ASONs) are one of the new classes of molecularly targeted agents that have transitioned from the laboratory into clinical trials. Rational drug design has resulted in agents directed against a number of important cellular targets, including the mRNA of bcl-2, protein kinase (PK) C-alpha, PK...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2003.s.007

    authors： Davies AM,Gandara DR,Lara PN Jr,Mack PC,Lau DH,Gumerlock PH

    更新日期：2003-01-01 00:00:00

  • Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns.

    abstract：BACKGROUND:Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2018.08.015

    authors： Farrell MJ,Yahya JB,Degnin C,Chen Y,Holland JM,Henderson MA,Jaboin JJ,Harkenrider MM,Thomas CR Jr,Mitin T

    更新日期：2019-01-01 00:00:00

  • Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.

    abstract：:There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival ad...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2011.06.002

    authors： Carbone DP,Felip E

    更新日期：2011-09-01 00:00:00

  • Combined-modality therapy for inoperable non-small-cell lung cancer using gemcitabine.

    abstract：:Combined-modality therapy with chemotherapy and radiation appears to be the most efficacious therapeutic modality for patients with locally advanced non-small-cell lung cancer. Most of the trials exploring this approach have utilized older agents such as cisplatin, vinblastine, and etoposide. Recent data suggest that ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2002.s.003

    authors： Curran WJ Jr

    更新日期：2002-03-01 00:00:00

  • Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.

    abstract：BACKGROUND:This study assesses the predictive and prognostic roles of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) during chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Changes in serum levels of sICAM-1 and VEG...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.009

    authors： Qian Q,Zhan P,Yu L,Shi Y,Cheng J,Wei S,Wang Q,Song Y

    更新日期：2011-03-01 00:00:00

  • Cooperative group research endeavors in small-cell lung cancer: current and future directions.

    abstract：:The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations ...

    journal_title：Clinical lung cancer

    pub_type：

    doi：10.3816/CLC.2009.n.044

    authors： Sangha R,Lara PN Jr,Adjei AA,Baas P,Choy H,Gaspar LE,Goss G,Saijo N,Schiller JH,Vokes EE,Gandara DR

    更新日期：2009-09-01 00:00:00

  • Undertreatment of elderly patients with non-small-cell lung cancer.

    abstract：:The absolute number of patients with lung cancer is rising as a result of our aging population. Until recently, clinicians have been reluctant to aggressively treat elderly patients with non-small-cell lung cancer (NSCLC) because of a lack of supportive data and concern for potential toxicity. Recently, evidence has e...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2005.n.031

    authors： Ng R,de Boer R,Green MD

    更新日期：2005-11-01 00:00:00

  • Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

    abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.007

    authors： Russell K,Healy B,Pantarotto J,Laurie SA,MacRae R,Sabri E,Wheatley-Price P

    更新日期：2014-05-01 00:00:00

  • Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.

    abstract：UNLABELLED:Non–small-cell lung carcinoma (NSCLC) (n = 65) were analyzed for promoter methylation of RASSF1A, CDH13, MGMT, ESR1, and DAPK genes in matching lung tumors, normal lung tissue, and blood samples. Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC. Hypermethylation ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.11.003

    authors： Kontic M,Stojsic J,Jovanovic D,Bunjevacki V,Ognjanovic S,Kuriger J,Puumala S,Nelson HH

    更新日期：2012-07-01 00:00:00

  • EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.

    abstract：INTRODUCTION:Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non-small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential t...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.06.005

    authors： Chang Q,Xu J,Qiang H,Teng J,Qian J,Lv M,Zhang Y,Lou Y,Zhao Y,Zhong R,Han B,Chu T

    更新日期：2020-07-06 00:00:00

  • Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.

    abstract：INTRODUCTION:Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2012.03.012

    authors： Tamiya M,Kobayashi M,Morimura O,Yasue T,Nakasuji T,Satomu M,Kohei O,Takayuki S,Morishita N,Suzuki H,Sasada S,Okamoto N,Hirashima T,Kawase I

    更新日期：2013-01-01 00:00:00

  • Radiation dose intensification in limited-stage small-cell lung cancer.

    abstract：:Multiple studies have confirmed the value of radiation therapy in limited-stage small-cell lung cancer. The appropriate dose of radiation and the optimal fractionation scheme, however, remain controversial. This article will examine the history of radiation therapy in the management of small-cell lung cancer. It will ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2003.n.013

    authors： Roof KS,Fidias P,Lynch TJ,Choi NC

    更新日期：2003-05-01 00:00:00

  • A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.

    abstract：BACKGROUND:The aim of this trial was to determine feasibility of incorporating bevacizumab (B) into concurrent chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Patients with unresectable stage III NSCLC, performance status of 0 to 1, and adequate organ function were...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2014.12.014

    authors： Wozniak AJ,Moon J,Thomas CR Jr,Kelly K,Mack PC,Gaspar LE,Raben D,Fitzgerald TJ,Pandya KJ,Gandara DR

    更新日期：2015-09-01 00:00:00

  • Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

    abstract：BACKGROUND:The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.02.002

    authors： Lin C,Chen X,Li M,Liu J,Qi X,Yang W,Zhang H,Cai Z,Dai Y,Ouyang X

    更新日期：2015-09-01 00:00:00

  • Complications of ablative therapies in lung cancer.

    abstract：:Two cases of complications secondary to the use of microwave ablation (MWA) in non-small-cell lung cancer (NSCLC) are discussed herein. The first case involves a 62-year-old man with stage IB NSCLC who declined surgery and pursued MWA. Within 7 months, he had residual disease at the MWA treatment site, and surgery was...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.019

    authors： Padda S,Kothary N,Donington J,Cannon W,Loo BW Jr,Kee S,Wakelee H

    更新日期：2008-03-01 00:00:00

  • Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.

    abstract：UNLABELLED:Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. M...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.05.001

    authors： Carpentier O,Selvaggi L,Jégu J,Purohit A,Prim N,Velten M,Quoix E

    更新日期：2015-11-01 00:00:00

  • Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.

    abstract：BACKGROUND:The real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is unclear. We compared US patients who received second-line therapy for non-small-cell lung cancer (NSCLC) before and shortly after US Food and Drug Administration (FDA) approval of PD-L1 inhibitors. PATIENTS AND METHODS:Patients in ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2019.04.004

    authors： Schwartzberg L,Korytowsky B,Penrod JR,Zhang Y,Le TK,Batenchuk C,Krug L

    更新日期：2019-07-01 00:00:00

  • Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

    abstract：:Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2016.10.009

    authors： Gerber DE,Urbanic JJ,Langer C,Hu C,Chang IF,Lu B,Movsas B,Jeraj R,Curran WJ,Bradley JD

    更新日期：2017-05-01 00:00:00

  • Role of topoisomerase I inhibitors in small-cell lung cancer.

    abstract：:Lung cancer continues to be the leading cause of cancer-related death in the United States. Small-cell lung cancer constitutes 15%-20% of all cases of lung cancer. It is a chemosensitive disease with an overall response rate of 70%-90% in first-line treatment. However, the majority of patients relapse, and further tre...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.010

    authors： Shihabi S,Belani CP

    更新日期：2001-05-01 00:00:00

  • Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

    abstract：BACKGROUND:It is unclear what proportion of VTE events in lung cancer patients are incidentally discovered and whether incidental events affect mortality. PATIENTS AND METHODS:We conducted a retrospective cohort study of lung cancer patients seen at the University of Rochester between January 1, 2006 and December 31, ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.06.003

    authors： Connolly GC,Menapace L,Safadjou S,Francis CW,Khorana AA

    更新日期：2013-11-01 00:00:00

  • Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.

    abstract：BACKGROUND:Molecular studies have demonstrated actionable driver oncogene alterations are more frequent in never-smokers with non-small-cell lung cancer (NSCLC). The etiology of these driver oncogenes in patients with NSCLC remains unknown, and environmental tobacco smoke (ETS) is a potential cause in these cases. MAT...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.01.005

    authors： Soo RA,Kubo A,Ando M,Kawaguchi T,Ahn MJ,Ou SI

    更新日期：2017-09-01 00:00:00

  • Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

    abstract：BACKGROUND:Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS:From 2008 to 2011, 130 ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.01.006

    authors： Zenke Y,Yoh K,Matsumoto S,Umemura S,Niho S,Ohmatsu H,Goto K,Ohe Y

    更新日期：2016-09-01 00:00:00

  • Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects.

    abstract：INTRODUCTION:Maintenance therapy is a new treatment paradigm for advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to evaluate its clinical efficacy in NSCLC and compared the efficacy of chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and other treatment ap...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.cllc.2015.01.002

    authors： Zhang C,Huang C,Wang J,Wang X,Li K

    更新日期：2015-09-01 00:00:00

  • Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine.

    abstract：BACKGROUND:Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. METHODS:Extrusion-precipitation method and DNA methy...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.09.005

    authors： Qiu X,Liang Y,Sellers RS,Perez-Soler R,Zou Y

    更新日期：2016-05-01 00:00:00

  • A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

    abstract：:Docetaxel has demonstrated activity as a radiosensitizer in numerous preclinical studies, probably due to its role as a cell cycle synchronizer for the G2/M radiosensitive phase of the cell cycle. We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of docetaxel...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2000.s.006

    authors： Choy H,DeVore RF,Hande KR,Porter LL,Rosenblatt PA,Slovis B,Laporte K,Shyr Y,Johnson DH

    更新日期：2000-04-01 00:00:00

  • Emerging antiangiogenic agents in lung cancer.

    abstract：:The success of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in numerous tumor types including non-small-cell lung cancer (NSCLC) has spurred the development of additional novel antiangiogenic agents with distinct mechanisms of action. These include the small-molecule receptor tyrosine kinase...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2006.n.010

    authors： Lee D,Heymach JV

    更新日期：2006-03-01 00:00:00

  • Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.

    abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.017

    authors： Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

    更新日期：2001-08-01 00:00:00